secwatch / observer
8-K filed March 9, 2026, 7:59 PM ET ticker RLMD CIK 0001553643
other material confidence high sentiment positive materiality 0.85

Relmada raises $160M private placement; NDV-01 12-month Phase 2 CR rate 76%

RELMADA THERAPEUTICS, INC.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

RELMADA THERAPEUTICS, INC. entered into Securities Purchase Agreement with certain institutional and accredited investors valued at approximately $160.0 million (effective 2026-03-09).

Action
entry
Agreement
equity purchase
Counterparty
certain institutional and accredited investors
Value
approximately $160.0 million
Effective
2026-03-09
Exact text from the filing
On March 9, 2026, Relmada Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) for a private placement (the “Private Placement”) with certain institutional and accredited investors (each, a “Purchaser” and collectively, the “Purchasers”).
View on SEC.gov

319 material agreements filed in the last 30 days. Browse all material agreements →

RELMADA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR
accession 0001213900-26-024918
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.